Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
Principal Investigator
Brian Schwartz
Photo of Brian Schwartz
Brian Schwartz

Description

Summary

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Keywords

Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous New World Cutaneous or Mucocutaneous Leishmaniasis Leishmaniasis Antimony Sodium Gluconate sodium stibogluconate (Pentostam)

Eligibility

You can join if…

Open to people ages 18 years and up

  • Biopsy proven new world cutaneous or mucocutaneous leishmania

You CAN'T join if...

  • Prolonged QT
  • Liver disease
  • Pancreatitis

Location

  • University of CA at San Francisco Hospitals and Clinics not accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Brian Schwartz
    Brian Schwartz is a physician specializing in the treatment of infectious diseases. His clinical and research interests include the diagnosis, treatment, and prevention of infections in immunocompromised patients. He serves as the Vice Chief for Clinical Affairs in the Division of Infectious Diseases.

Details

Status
not accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT00508963
Study Type
Expanded Access
Last Updated